The Leishmaniasis (Kala-Azar) drugs in development market research report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Leishmaniasis (Kala-Azar). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued products.
GlobalData tracks 51 drugs in development for Leishmaniasis (Kala-Azar) by 36 companies/universities/institutes. The top development phase for Leishmaniasis (Kala-Azar) is preclinical with 21 drugs in that stage. The Leishmaniasis (Kala-Azar) pipeline has 20 drugs in development by companies and 31 by universities/ institutes. Some of the companies in the Leishmaniasis (Kala-Azar) pipeline products market are: Drugs for Neglected Diseases initiative, Central Drug Research Institute and Foundation For Neglected Disease Research.
The key targets in the Leishmaniasis (Kala-Azar) pipeline products market include Proteasome, Purine Nucleoside Phosphorylase, and Nucleotide Binding Oligomerization Domain Containing Protein 2.
The key mechanisms of action in the Leishmaniasis (Kala-Azar) pipeline product include Proteasome Inhibitor with two drugs in Phase II. The Leishmaniasis (Kala-Azar) pipeline products include five routes of administration with the top ROA being Oral and nine key molecule types in the Leishmaniasis (Kala-Azar) pipeline products market including Small Molecule, and Live Attenuated Vaccine.
Leishmaniasis (Kala-Azar) overview
Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen, and fever. Treatment includes anti-parasitic drugs.
For a complete picture of Leishmaniasis (Kala-Azar)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
